...
首页> 外文期刊>Pharmacopsychiatry >Cholesterol Modulates Amyloid Beta-peptide's Membrane Interactions.
【24h】

Cholesterol Modulates Amyloid Beta-peptide's Membrane Interactions.

机译:胆固醇调节淀粉样β肽的膜相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The causal relationship between amyloid beta-peptide (Abeta) deposition and Alzheimer's disease (AD)-specific neuropathological lesions such as neurodegeneration and cortical atrophy is still not known. Mounting evidence points to alterations in cholesterol homeostasis occurring in AD brain that are probably linked to cerebral Abeta pathology. Interestingly, cholesterol not only modulates Abeta synthesis, but also controls interactions between Abeta and neuronal membranes that are regarded as decisive in the initiation of a neurotoxic cascade. This review focuses on the impact of cholesterol on membrane disordering effects of Abeta. Cholesterol is known to be an essential modulator of physicochemical state and functional activity in physiological membranes, and thus plays an essential role in the regulation of synaptic function and cell plasticity. In vitro and in vivo modulation of membrane cholesterol levels affect different cholesterol pools within the plasma membrane bilayer that are differentiallysensitive to Abeta's disrupting effects. Membrane acyl-chains in the hydrocarbon core are most susceptible to Abeta. In this membrane region, cholesterol attenuates the membrane disordering effects of Abeta. This cholesterol pool is modulated by methyl-beta-cyclodextrin (MbetaCD) treatment in vitro. On the other hand, statin treatment in vivo depletes a cholesterol pool in a membrane area, which is much less susceptible to Abeta's membrane-disrupting effects. Our findings clearly implicate an involvement of cholesterol in brain membrane alterations occurring during AD. Disease-related changes in membrane cholesterol metabolism may be subtle and restricted to defined membrane pools since total membrane cholesterol levels are mainly unchanged in AD brain. Thus, elucidation of the structure and function of different cholesterol pools is necessary in understanding the coherence between cholesterol and AD. Abbreviations. Abeta:amyloid beta-peptide ADAlzheimer's disease; ApoEapolipoprotein E APPamyloid beta-peptideprecursor protein BBBblood brain barrier CHOD-PAP-cholesteroloxidase-peroxidase-aminophenazonmethodphenol method CNScentral nervous system DPHdiphenylhexatriene HMG-CoAhydroxymethylglutaryl-coenzyme A MbetaCDmethyl-beta-cyclodextrin PMplasma membrane SPMsynaptosomal plasma membrane SUVsmall unilammelar vesicle TNBStrinitrobenzensulfonic acid TMA-DPHtrimethylammonium-diphenylhexatriene
机译:淀粉样蛋白β肽(Abeta)沉积与阿尔茨海默氏病(AD)特异性神经病理病变(例如神经退行性病变和皮质萎缩)之间的因果关系仍然未知。越来越多的证据表明,AD脑中胆固醇稳态的改变可能与脑Abeta病理学有关。有趣的是,胆固醇不仅可以调节Abeta的合成,还可以控制Abeta和神经元膜之间的相互作用,而神经元膜被认为是神经毒性级联反应的决定性因素。这篇综述着重于胆固醇对Abeta膜紊乱作用的影响。已知胆固醇是生理膜中生理化学状态和功能活性的必需调节剂,因此在突触功能和细胞可塑性的调节中起着至关重要的作用。膜胆固醇水平的体外和体内调节会影响质膜双层内不同的胆固醇库,这些库对Abeta的破坏作用具有不同的敏感性。烃芯中的膜酰基链最容易受到Abeta的影响。在这个膜区域,胆固醇减弱了Abeta的膜紊乱作用。该胆固醇库在体外通过甲基-β-环糊精(MbetaCD)处理进行调节。另一方面,他汀类药物在体内的治疗会消耗膜区域的胆固醇,这对Abeta的膜破坏作用不那么敏感。我们的发现清楚地表明胆固醇参与了AD期间发生的脑膜改变。与疾病相关的膜胆固醇代谢变化可能是微妙的,并且仅限于定义的膜池,因为总膜胆固醇水平在AD脑中主要保持不变。因此,阐明不同胆固醇库的结构和功能对于理解胆固醇和AD之间的一致性是必要的。缩写。 Abeta:淀粉样β肽AD阿兹海默氏病; ApoEapolipoprotein E APP淀粉样蛋白β-肽前体蛋白BBB

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号